Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
about
Moving towards effective therapeutic strategies for Neuronal Ceroid LipofuscinosisIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAAgile delivery of protein therapeutics to CNSPharmacological chaperone therapy for lysosomal storage diseases.Gene therapy for neurologic manifestations of mucopolysaccharidoses.Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptorEngineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrierPharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.Vascular Pathology as a Potential Therapeutic Target in SCI.Current and potential therapeutic strategies for mucopolysaccharidoses.Targeted delivery of protein and gene medicines through the blood-brain barrier.Nanotechnology applied to treatment of mucopolysaccharidoses.RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 tExpanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Q26753109-A2B3E839-E1C1-4B7C-AC4F-5DC05681404DQ28660580-11F4F40F-E271-452A-B824-47494FA84E68Q34079647-D176667D-961A-48CF-A910-92DB3B08226FQ35214286-8E9233FA-033C-4F45-8026-5D4C1FE548B6Q35362251-0786F14D-A83F-4E82-82FE-69E91D382162Q36296187-7EE07B61-F7EB-4FCA-9081-8049E22236EDQ36546138-CEF4B316-BAA1-42EC-97D9-56FE3280587EQ36565901-B61AC714-3B50-447D-9BFF-257056D1AA12Q36637219-9BCC689F-CAE9-4F4C-A05A-500B1DF2BB99Q37573901-9E591F20-1299-4FCF-A3CF-11889FF8C96FQ38170038-DD5377F5-1CE7-40BD-BA9A-16AEA2E5DFA8Q38194635-FFA370EC-115A-427C-A15E-0DD7174135D0Q38351122-50115AC8-24AC-4017-8B5D-F51858AB4FE8Q38850942-827E7D08-22F1-4199-80C2-1AF3B226E1DBQ45875364-20AFFF16-23C9-4CA1-8EC1-CF4E5347B445Q45931498-39BB2716-3A85-4141-B6D8-AFD79AACE674Q57677272-F5FBED7F-4D94-4422-A7A2-3E922D682933Q58724935-61770FE8-6EBA-44FA-80C5-C0C40A2E6DC5
P2860
Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@en
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@nl
type
label
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@en
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@nl
prefLabel
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@en
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@nl
P2093
P356
P1476
Reversal of lysosomal storage ...... se-iduronidase fusion protein.
@en
P2093
Eric Ka-Wai Hui
Jeff Zhiqiang Lu
Qing-Hui Zhou
P304
P356
10.1021/MP200136X
P407
P577
2011-06-17T00:00:00Z